India to create 100 crore corona vaccine, UK and Pune companies ready for agreement

India to create 100 crore corona vaccine, UK and Pune companies ready for agreement

Scientists from all over the world are engaged in scientific efforts to make the corona virus vaccine. India including America, China, Britain, Germany etc. are also included in this race. There is now a big relief news from India about the success of the vaccine. The good news for the countrymen is that preparations have started for its production in India amid the trials being conducted on the vaccine. Indeed, the Pune-based Serum Institute of India (SII) lab is preparing to produce and supply the corona virus vaccine. 

British-Swedish pharma company AstraZeneca has announced that it has joined hands with India to supply the vaccine AZD1222 and is in a licensing agreement with SII. Oxford University has given the responsibility of supplying Corona its potential vaccine to the company AstraZeneca. AstraZeneca and SII together are preparing to make a billion or 100 crore vaccine. Of this, 400 million vaccines are targeted to be supplied by the end of this year. The Corona virus vaccine produced in Pune will be supplied to low-income countries including India. Let us know that Oxford University is at the forefront of the race to make the Corona vaccine. Here the vaccine trial has reached the second stage.

Recently Oxford University has announced Phase II and Phase III trials of a vaccine that will cover 10,000 adults. SII's lab currently produces 20 types of vaccines for 165 countries and every year millions of vaccines are supplied from here. But this time CEO Honor Poonawala is very excited about the responsibility given to this company. SII has played a major role in the production and supply of vaccines globally over the last 50 years, at the forefront of Oxford's vaccine trials.

SII is currently working on vaccine candidates developed by UK's Oxford, America's Codegenics and Australia's biotech farm Themis. But Poonawala has the highest expectations from the Oxford University vaccine as it leads the trial. In addition, SII is also developing its own vaccine.